pSivida touts 12-month data from Ph3 trial of Durasert ocular insert

pSivida (NSDQ:PSDV) touted results today from a second Phase III trial that the company conducted for its three-year posterior segment uveitis treatment. The 153-patient study found that there was a significant reduction in the recurrence of posterior segment uveitis through 12 months in the group treated with pSivida’s drug-releasing ocular insert, Durasert. Get the full story at our sister site, Drug Delivery Business News. The post pSivida touts 12-month data from Ph3 trial of Durasert ocular insert appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat pSivida Corp. Source Type: news